N/A
N=45
Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy
HIV · AIDS · Peripheral Neuropathy · Pain · Sleep
Bottom Line
View on ClinicalTrials.gov: NCT01419314 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Jan 2013
Primary outcome: Primary: Pain Scores at Week 3 — 50.53; 53.76 units on a scale 0-100 (0= no pain)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Splinting application to the lower extremities (Device); Splint liner application (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Texas Woman's University
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Scores at Week 3 |
50.53; 53.76 | — |
| PRIMARY Pain Scores |
40.22; 49.89 | 0.001 sig |
| PRIMARY Sleep Quality/Quantity Scores (PSQI) |
12.06; 11.95 | — |
| PRIMARY Sleep Quality/Quantity Scores (PSQI) |
12.06; 11.95 | — |
| SECONDARY Function-Reach |
40.00; 39.34 | — |
| SECONDARY Function-Reach |
40.00; 39.34 | — |
| SECONDARY Function-Walking Distance |
279.52; 304.90 | — |
| SECONDARY Function-Walking Distance |
279.52; 304.90 | — |
Summary
WHAT IS THE PURPOSE OF THIS STUDY? The investigators want to know if wearing a pair of splints at night works to bring the pain down and help you sleep better (in people living with HIV/AIDS related neuropathy).
HOW MANY PEOPLE WILL PARTICIPATE? About 58 to 88 people will take part in this study at the Harris County Hospital District (HCHD).
WHAT WILL HAPPEN DURING THIS STUDY? As a participant, you will be assigned to one of two treatment groups. In one group, you will be asked to wear leg splints at night and the other you will wear the liners of the splints only.
You will be asked to answer questions about how well you sleep, how long you sleep, and about your discomfort at the legs. The researcher will be there to help, but the investigators want you to answer the questions on your own if you can. You will be asked to reach forwards standing next to a wall and to walk for 6 minutes after that. The tests will de done in random order. The sessions will be done at the beginning, at week three and week six. You should finish all of the testing and questionnaires in an hour or less, for a total of three hours over six weeks in the investigators clinic.
You will receive instructions on how to use the splints with liners or the liners alone at home. You will be asked to wear them at night only for the next 6 weeks. Finally, the principal investigator will contact you weekly by phone, to discuss issues of comfort and your ability to adhere to the instructions provided.
Eligibility Criteria
Inclusion Criteria
- Adult PLWA 18 and older, with a clinical diagnosis of symptomatic bilateral LE PN will be invited to participate.
- The participants will be on a stable pain and HIV/AIDS management regimen without foreseeable alterations or changes to said pharmacological regimen, which may include pain and or sleep medications.
- The participants will be community dwelling individuals, able to walk at or above a modified independence level with or without the need of an assistive device to ambulate, such as a cane or walker.
- Eligible participants will report at least one of the following clinical symptoms: paresthesia, dysesthesia, and report night cramps in the LE
Exclusion Criteria
- Participants will be excluded if they have a clinical diagnosis of any of the following: significant cardiovascular or pulmonary disease (specifically, myocardial infarction within the past six months, angina, or dyspnea at rest), paraplegia, hemiplegia, other major neurological dysfunction, diabetes, absent pedal pulse during examination, sleep apnea, or are pregnant.
- Additionally, patients unable to read English, patients with changes to their pharmacological management during the study and or using any mechanical devices to assist in normalizing sleep will be excluded from this study.
Data sourced from ClinicalTrials.gov (NCT01419314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.